BioSpace News Archive

Terran Biosciences, Inc has been awarded patent US 11,958,821 from the United States Patent and Trademark Office (USPTO) covering the world’s first new salts and polymorphs of MDMA (MDMA hemifumarate), pharmaceutical compositions using these forms, and the method of use for treating post-traumatic stress disorder (PTSD).

Codone Biotechnology will present data on its lead tRNA candidates at the poster session for Late Breaking Abstract of the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on Wednesday, May 8, 2024.

Nevro Corp. today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024.

NRx Pharmaceuticals today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin.

Outset Medical, Inc. announced today a multi-year agreement to help accelerate home hemodialysis in the U.S.

Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.

Allurion Technologies, Inc. today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).

G1 Therapeutics, Inc will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET.

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a milestone of testing over 80,000 patients for Rh incompatibility, which develops when a pregnant patient has Rh-negative blood and the baby has Rh-positive blood.

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced it will partner with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516.